✦ LIBER ✦

9000 ORAL Epidermal Growth Factor Receptor (EGFR) Expression as a Predictive Biomarker of Survival in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving First-Line Therapy With Cetuximab Combined With Chemotherapy in the FLEX Trial

✍ Scribed by O'Bvrne, K.; Paz-Ares, L.; Pereira, J.R.; von Pawel, J.; Ramlau, R.; Störkel, S.; Schumacher, K.M.; von Heydebreck, A.; Celik, I.; Pirker, R.

Book ID: 123397657
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 43 KB
Volume: 47
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(11)72312-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9019 POSTER DISCUSSION Safety Analysis o

9019 POSTER DISCUSSION Safety Analysis of Patient Subgroups Defined by Low and High Tumour Epidermal Growth Factor Receptor (EGFR) Expression in FLEX Study Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy With or Without Cetuximab as First-Line Therapy

✍ von Pawel, J.; Pirker, R.; Pereira, J.R.; Krzakowski, M.; Park, K.; Eberhardt, W 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

EGFR expression as a predictor of surviv

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

✍ Robert Pirker; Jose R Pereira; Joachim von Pawel; Maciej Krzakowski; Rodryg Raml 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 872 KB

First-cycle rash and survival in patient

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study

✍ Ulrich Gatzemeier; Joachim von Pawel; Ihor Vynnychenko; Petr Zatloukal; Filippo 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 220 KB

55 Randomized phase II clinical trial of

55 Randomized phase II clinical trial of cetuximab in combination with cisplatin (C) and vinorelbine (V) or CV alone in patients with advanced epidermal growth factor receptor (EGFR)-expressing non-small-cell lung cancer (NSCLC)

✍ R. Rosell; R. Ramlau; A. Szczesna; C. Daniel; M. Bertrand; R. Garcia-Arroyo; K. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

O-245 Randomized phase II clinical trial

O-245 Randomized phase II clinical trial of cetuximab in combination with cisplatin and vinorelbine or cisplatin and vinorelbine alone in patients (pts) with advanced epidermal growth factor receptor (EGFR)-positive non-small-cell lung cancer (NSCLC)

✍ Rosell, Rafael; Constenla, Manuel; Kolb, Rainer; Pfeiffer, Wolfang; O'Bryne, Ken 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 178 KB

A phase II study of Erbitux (IMC-C225),

A phase II study of Erbitux (IMC-C225), an Epidermal Growth Factor Receptor (EGFR) blocking ntibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced Non-Small Cell Lung Cancer (NSCLC)

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 157 KB